A freedom-to-operate (FTO) analysis is the process of determining whether commercializing a specific product or process would infringe valid, enforceable patent claims in a given jurisdiction. Biotech founders encounter this term during investor conversations, patent attorney discussions, and due diligence checklists, often without a clear picture of what it costs, when to commission one, or what happens if they skip it. This guide gives you that picture.
What FTO Analysis Is — and What It Does Not Cover
FTO analysis and a patentability search answer fundamentally different questions. FTO asks whether you can sell; patentability asks whether you can protect. A product can be entirely patentable and still infringe a third-party patent. Founders who conflate the two questions often discover the distinction at the worst possible moment: during Series A due diligence or after manufacturing scale-up.
The output of an FTO analysis is a legal opinion, not a binary clearance certificate. A qualified patent attorney assigns risk levels to identified patents based on claim scope, validity, and jurisdictional coverage. That opinion informs a commercial decision. It does not eliminate IP risk entirely, and any attorney or service that implies otherwise is misrepresenting the process.
FTO analysis also has a time-limited validity. New patents publish continuously. A clearance opinion from two years ago may not reflect the current patent position for your product category, particularly in fast-moving areas like gene editing or RNA therapeutics.
Why Biotech FTO Is More Complex Than Standard Patent Clearance
Approximately 80% of biopharmaceutical patents contain amino acid or nucleic acid sequence claims. These claims require specialised database searches using sequence alignment tools against patent sequence databases. Standard keyword searches miss a significant portion of the relevant IP. If your FTO search doesn’t include sequence-specific analysis, it isn’t complete.
Layered IP Stacks in Gene Editing
Biotech IP is layered in ways that other technology sectors rarely encounter. A single CRISPR-based therapeutic, where CRISPR-Cas9 is a gene-editing tool that uses a guide RNA to direct a protein to cut specific DNA sequences, may sit beneath foundational platform patents, delivery mechanism patents, and indication-specific composition claims. These are often held by different entities. The Broad Institute and UC Berkeley hold competing foundational CRISPR patent families. Delivery mechanisms, such as lipid nanoparticles used in mRNA delivery, carry their own patent families. Therapeutic applications add another layer. You could infringe three separate patent holders without touching the same claim twice.
Biologics and Regulatory Exclusivity Interactions
Biologics and biosimilars face additional complexity because patent term extensions, data exclusivity periods, and regulatory exclusivities interact with FTO in ways that small-molecule drug analysis doesn’t encounter. A biologic may be patent-clear but still blocked from market entry by regulatory data exclusivity. Your FTO attorney needs to understand both patent law and the regulatory pathway for your product class.
When to Commission an FTO Analysis: Five Development Stage Triggers
The most common mistake early-stage founders make is treating FTO as a pre-launch formality. By that point, redesigning around a blocking patent costs far more than the original FTO opinion would have. Commission FTO analysis at these five trigger points:
- Before significant R&D commitment: Run a preliminary FTO search before you commit to a specific molecular target, delivery platform, or manufacturing process that would be costly to redesign.
- Before IND filing: A full FTO opinion is standard practice before submitting an Investigational New Drug application to regulators. It documents that you assessed third-party IP risk before entering clinical development.
- Before Series A fundraising: Institutional investors treat IP stack quality as directly predictive of licensing cost structure. Arriving without a current FTO opinion signals either naivety or deliberate avoidance.
- Before licensing or partnership negotiation: Any agreement where you make IP representations requires a documented basis for those representations. An FTO opinion provides that basis.
- Before geographic expansion: Patent rights are jurisdiction-specific. An FTO opinion covering the USPTO doesn’t address EPO-granted patents. If you’re entering European markets, you need European coverage.
The cost argument is straightforward. FTO analysis costs approximately 0.02% of the R&D investment it protects, and 0.02% of the cost of a Phase 3 trial alone. Framing it as expensive relative to the risk it mitigates is a miscalculation most founders make only once.
How an FTO Analysis Is Conducted
The process begins with a precise technical definition of the product or process being assessed. Claim scope in the FTO opinion is only as accurate as the technical specification you provide to the attorney. Vague inputs produce vague outputs.
The Six-Step FTO Process
- Define scope: Specify the exact product or process, including molecular structure, delivery mechanism, therapeutic indication, and target markets.
- Identify databases and jurisdictions: Cover issued patents and published applications across relevant jurisdictions, including sequence-specific databases for biologics and nucleic acid therapeutics.
- Conduct the search: Use both keyword and sequence-based search methods. For biologics, BLAST-based tools against patent sequence databases are required.
- Analyze claim scope and validity: Assess each identified patent for claim breadth, validity, enforceability, and jurisdictional coverage. Not every flagged patent represents genuine blocking risk.
- Assess infringement risk: Map your product’s technical features against the claims of each relevant patent. Assign risk tiers: low, medium, or high.
- Deliver the opinion with mitigation options: A credible FTO opinion includes search methodology, claim mapping, risk assessment for each patent, and recommended risk mitigation strategies.
Sequence claims account for approximately 30% of all biopharma patent claims and are among the most technically precise. A single amino acid substitution can move a biologic outside the literal scope of a blocking claim. This is why technical precision in the FTO specification matters at step one, not step five.
Options When an FTO Analysis Identifies a Blocking Patent
A high-risk finding doesn’t automatically stop your programme. It means you need to evaluate your options before commercialisation, not after. Four paths are available:
- Design-around: Modify the product or process to fall outside the claim scope of the blocking patent. Feasible in early development; increasingly costly as you approach clinical-stage manufacturing commitments. This is the strongest argument for early FTO commissioning.
- Licensing: Negotiate a licence from the patent holder. The FTO opinion informs your negotiating position and helps you assess whether licensing costs are commercially viable relative to projected revenues.
- Validity challenge: File an inter partes review (IPR), which is a USPTO proceeding that allows third parties to challenge a granted patent’s validity based on prior art, or an equivalent opposition at the EPO. A viable strategy when the blocking patent is of questionable quality, but it requires time and legal resource.
- Freedom-to-operate by expiry: If the blocking patent expires within your development timeline, you may be able to time your commercial launch accordingly. Relevant for products with long development horizons.
What’s your realistic option if you skip FTO entirely and discover a blocking patent after Phase 2 completion? At that point, design-around requires clinical redesign, licensing negotiations happen from a position of desperation, and validity challenges delay your launch by years. The math on early FTO is not subtle.
FTO Position, Valuation, and Investor Due Diligence
Institutional investors evaluating biotech companies treat the IP stack as directly predictive of licensing cost structure. A weak FTO position can reduce unadjusted DCF valuation by up to 40% in a worst-case scenario. DCF, or discounted cash flow valuation, projects future revenues and discounts them to present value; unresolved IP risk compresses those projections at every stage.
Series A and Series B due diligence processes routinely include IP reviews. In licensing and partnership negotiations, a credible FTO opinion strengthens your position by demonstrating that you’ve assessed third-party IP risk and can represent your freedom to commercialise with a documented basis.
Building FTO Into Your Biotech IP Strategy
FTO analysis belongs inside your IP strategy alongside patentability assessments, provisional filing decisions, and freedom-to-use evaluations for research tools. For platform companies whose technology applies across multiple indications, a modular FTO approach assessing the platform separately from each application is more efficient than commissioning a full opinion for every product.
The practical path forward: commission a preliminary FTO search before your next significant R&D commitment, and schedule a full opinion before any investor representation or regulatory submission that requires IP clarity. Engage a patent attorney with biopharmaceutical experience, not a generalist IP firm, because the sequence claim and biologics complexity requires domain-specific knowledge that general patent practice doesn’t cover. Your IP position is a commercial asset. Treat it accordingly.
Frequently Asked Questions About FTO Analysis
How much does an FTO analysis cost in biotech?
A preliminary FTO search typically costs several thousand pounds or dollars depending on scope and jurisdiction. A full FTO opinion with claim mapping and risk assessment for a biopharmaceutical product can range from tens of thousands upward, depending on the complexity of the IP field and number of jurisdictions covered. At approximately 0.02% of Phase 3 trial costs, it represents a small fraction of the investment it protects.
How long does an FTO analysis take?
A preliminary search can be completed in two to four weeks. A full FTO opinion with detailed claim analysis typically takes six to twelve weeks, depending on the complexity of the technology area and the number of patents identified in the initial search. Plan for this timeline when scheduling pre-IND or pre-fundraising milestones.
What is the difference between an FTO and a patent landscape?
A patent landscape maps the broader IP territory in a technology area, identifying key players, filing trends, and white spaces. An FTO opinion assesses whether your specific product infringes specific claims. A landscape informs strategy; an FTO opinion informs a commercialisation decision. You need both, but they answer different questions and are not interchangeable.
Do I need an FTO analysis if I have my own patents?
Yes. Owning patents gives you the right to exclude others from your claims. It does not give you the right to commercialise your product if doing so infringes someone else’s patent. Your patents and your FTO position are separate questions with separate answers.
- Freedom-to-Operate Analysis in Biotech: What It Is and When You Need One - June 24, 2026
- GC Content Explained: Why It Matters for PCR and Sequencing Success - June 16, 2026
- SAFE Notes in Biotech: When They Work and When They Don’t - June 8, 2026